TPM3 and cancer: While data on the contribution of NTRK fusions in AML is rare, enhanced detection methods for gene fusions, along with increased exposure of TRK proteins as contributors to oncogenesis, may allow for TRK inhibitors to gain acceptance as a therapy for this cancer.